Drug & intervention

omeprazole

RxCUI 7646

Clinical trials23
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Omeprazole

Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. It can be taken by mouth or by injection into a vein. It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid and as Konvomep. Common side effects include nausea, vomiting, headaches, abdominal pain, and increased intestinal gas. Serious side effects may include Clostridioides difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer. Whether it is safe for use in pregnancy is unclear. It works by blocking the release of stomach acid. Omeprazole was patented in 1978 and approved for medical use in 1988. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the tenth most commonly prescribed medication in the United States, with more than 45 million prescriptions. It is also available without a prescription in the United States.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

23 shown
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)NCT06562907 · 2024-08-28
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07
RECRUITING
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNCT07862114 · 2026-10-16
NOT_YET_RECRUITING
Effect of Omeprazole on Gut Microbiota in Adults With Obesity and GERDNCT07850960 · 2026-09-25
NOT_YET_RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerNCT07214662 · 2026-01-13
TERMINATED
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult ParticipantsNCT07235748 · 2025-10-07
COMPLETED
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes MellitusNCT06279234 · 2024-02-20
COMPLETED
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersNCT05438303 · 2022-06-13
COMPLETED
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4NCT04246762 · 2021-11-16
COMPLETED
Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid MetabolisersNCT04198948 · 2019-03-04
COMPLETED
Effect of a Proton Pump Inhibitor on the PK of TepotinibNCT03531762 · 2018-05-14
COMPLETED
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinNCT03131973 · 2017-05-13
COMPLETED
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)NCT02950259 · 2017-02-09
COMPLETED
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant ChemotherapyNCT02595372 · 2015-11-12
COMPLETED
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsNCT02249871 · 2014-09-24
COMPLETED
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid ArthritisNCT01636557 · 2012-10-11
COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsNCT01596647 · 2012-05-01
COMPLETED
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisNCT01462318 · 2011-11-01
COMPLETED
Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesNCT01911728 · 2011-07-25
COMPLETED
Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese SubjectsNCT01136317 · 2010-04-01
COMPLETED
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose StudyNCT00942136 · 2009-07-01
COMPLETED
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)NCT01000818 · 2008-06-01
COMPLETED
Evaluation of Omeprazole Effect on GlaucomaNCT01000220
UNKNOWN

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.